Metastatic Hormone-sensitive Prostate Cancer Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total daily dose of 1200 mg, in addition to standard androgen deprivation therapy (ADT) and docetaxel. Subjects will be stratified at randomization for the extent of disease and for Alkaline Phosphatase levels. All subjects will be treated with ADT as standard therapy. Six cycles of docetaxel will be administered after randomization. The subjects considered for inclusion in the study will have metastatic prostate cancer and will be candidates for ADT and docetaxel. Treatment with darolutamide (ODM-201)/placebo will be administered until symptomatic progressive disease, change of antineoplastic therapy, unacceptable toxicity, until subject withdraws consent, withdrawal from the study at the discretion of the investigator or his/her designated associate(s), death, non-compliance, or if sponsor terminates the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05381311 -
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
|
||
| Active, not recruiting |
NCT00309985 -
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
|
Phase 3 | |
| Completed |
NCT03532217 -
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05059236 -
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
|
Phase 2 | |
| Not yet recruiting |
NCT06134271 -
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04934722 -
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
|
Phase 3 | |
| Not yet recruiting |
NCT06334120 -
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
|
||
| Recruiting |
NCT05901649 -
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
|
||
| Withdrawn |
NCT03343977 -
Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04191096 -
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
|
Phase 3 | |
| Active, not recruiting |
NCT03879122 -
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
|
Phase 2/Phase 3 |